Transplant Access Catalogue · 360°
Every transplant. Every line of therapy.
One accountable route.
A clinically anchored transplant formulary for solid-organ, haematopoietic stem-cell and tissue programmes — built for continuity of supply, safety governance and verified access.
82Formulary Lines
4Care Pillars
360°Pathway Coverage
DotLIFEAccess & Continuity
TACROLIMUS·MYCOPHENOLATE·BASILIXIMAB·ATG·VALGANCICLOVIR·RUXOLITINIB·DEFIBROTIDE·BELATACEPT·SOLID ORGAN·HSCT·TISSUE & OCULAR·
TACROLIMUS·MYCOPHENOLATE·BASILIXIMAB·ATG·VALGANCICLOVIR·RUXOLITINIB·DEFIBROTIDE·BELATACEPT·SOLID ORGAN·HSCT·TISSUE & OCULAR·
The Transplant Access Thesis
Not a volume category. A reliability category.
Transplant medicine is defined by narrow therapeutic windows, cold-chain biologics, and orphan complications where a delay can cost a graft or a life.
01
Continuity over price
We compete on verified supply and documentation — not on a single low unit cost that fails at the next reorder.
02
Protocol baskets
Induction, maintenance, and rescue supplied as coherent baskets aligned to the clinical pathway.
03
Safety & TDM
Narrow-therapeutic-index medicines carry monitoring guidance, interaction flags and brand-continuity discipline.
04
Fast named-patient
For orphan complications, a pre-prepared access pathway turns an emergency into a planned, authorised supply.
Consultant Note · Senior Nephrology & Transplant Medicine
“In a transplant programme the formulary is a safety system, not a price list. The questions that matter at the bedside are whether the calcineurin inhibitor brand is continuous, whether CMV and PJP prophylaxis are uninterrupted, and whether rescue biologics can be accessed within the clinical window.”
Pillar · Induction · Maintenance · Rejection
Solid Organ Transplant
TR-SOT-001Tacrolimus immediate-releaseCalcineurin inhibitor · Cap / IV
Kidney, liver, heart, lung, pancreas rejection prophylaxis.
MONITORING: Trough TDM by organ/time; renal function; glucose; BP.
TR-SOT-002Tacrolimus extended-releaseCalcineurin inhibitor · Cap/tab
Adherence-friendly once daily tacrolimus maintenance.
MONITORING: Trough TDM after conversion; verify brand/strength.
TR-SOT-003Cyclosporine modifiedCalcineurin inhibitor · Cap/oral/IV
Kidney, liver, heart transplant maintenance; CNI alternative.
MONITORING: Trough/C2 TDM; BP; creatinine; lipids.
TR-SOT-004Mycophenolate mofetilAntimetabolite · Tab/cap/IV
Kidney, heart, liver, lung maintenance in combinations.
MONITORING: CBC, GI tolerance, pregnancy avoidance.
TR-SOT-005Mycophenolate sodiumAntimetabolite · EC tablet
Enteric-coated alternative for GI-intolerant patients.
MONITORING: CBC; GI tolerance; pregnancy avoidance.
TR-SOT-006AzathioprineAntimetabolite · Tablet
Alternative maintenance when MMF not tolerated or pregnancy planning.
MONITORING: CBC, LFT, TPMT/NUDT15.
TR-SOT-007Prednisone / prednisoloneCorticosteroid · Tab/oral liq
Maintenance, tapering, rejection adjunct, tissue inflammation.
MONITORING: BP, glucose, weight, infection, bone health.
TR-SOT-008MethylprednisoloneCorticosteroid · PFI / IV
Pulse steroid for rejection, conditioning complications and GVHD.
MONITORING: Glucose, BP, infection, electrolytes.
TR-SOT-009BasiliximabIL-2 receptor antagonist · PFI / IV
Low/intermediate risk kidney; liver renal-sparing; lung/heart induction.
MONITORING: Infusion reaction; infection; documentation.
TR-SOT-010Anti-thymocyte globulinPolyclonal antibody · Vial / IV
High immunologic risk, delayed graft function risk, acute rejection.
MONITORING: CBC/platelets, infection prophylaxis, infusion.
TR-SOT-011AlemtuzumabAnti-CD52 mAb · IV/SC
Selected induction/desensitization; HSCT conditioning in protocols.
MONITORING: CBC/lymphocytes, infection prophylaxis, CMV.
TR-SOT-012SirolimusmTOR inhibitor · Tab/oral sol
CNI toxicity, BK nephropathy, recurrent malignancy, CAV in heart.
MONITORING: Trough TDM, lipids, proteinuria, wound healing.
TR-SOT-013EverolimusmTOR inhibitor · Tablet
Maintenance immunosuppression; malignancy/CNI-sparing niche.
MONITORING: Trough TDM where applicable, lipids.
TR-SOT-014BelataceptCo-stimulation blocker · IV
EBV-positive kidney transplant alternative to CNI; renal-sparing.
MONITORING: EBV status; infusion schedule; PTLD.
TR-SOT-015RituximabAnti-CD20 mAb · IV
ABO-incompatible desensitization, AMR, PTLD, HSCT complications.
MONITORING: HBV screening/prophylaxis; infusion reaction.
TR-SOT-016IVIGImmunomodulator · IV
AMR adjunct, desensitization, hypogammaglobulinemia.
MONITORING: Renal function, thrombosis risk, IgA risk.
TR-SOT-017BortezomibProteasome inhibitor · Vial/SC/IV
Refractory antibody-mediated rejection, plasma cell diseases.
MONITORING: CBC, neuropathy, herpes prophylaxis.
TR-SOT-018TocilizumabIL-6 receptor mAb · IV/SC
Refractory AMR protocols; cytokine syndromes and inflammatory complications.
MONITORING: LFT, neutrophils, infection/TB screening.
TR-SOT-019EculizumabComplement C5 inhibitor · IV
Complement-mediated TMA/aHUS recurrence; selected AMR/HSCT-TMA.
MONITORING: Meningococcal vaccination/prophylaxis.
Pillar · Mobilisation · Conditioning · GVHD · VOD
Haematopoietic Stem Cell Transplant
TR-HSCT-040Filgrastim (G-CSF)Growth factor · PFS/vial
Post-transplant neutropenia, stem-cell mobilization.
MONITORING: ANC, infection, bone pain.
TR-HSCT-041PegfilgrastimLong-acting G-CSF · PFS
Chemotherapy-related neutropenia support; selected mobilization.
MONITORING: ANC, bone pain.
TR-HSCT-042PlerixaforCXCR4 antagonist · Vial/SC
Autologous HSCT mobilization with G-CSF in poor mobilizers.
MONITORING: CD34 counts, WBC, timing with apheresis.
TR-HSCT-043CyclophosphamideAlkylator · Vial/tab
HSCT conditioning; post-transplant cyclophosphamide.
MONITORING: CBC, renal, hydration, mesna.
TR-HSCT-044BusulfanAlkylator · Tab/IV
Myeloablative/reduced-intensity HSCT conditioning.
MONITORING: PK/TDM, seizure prophylaxis, liver/VOD.
TR-HSCT-045FludarabinePurine analog · Vial/tab
RIC conditioning, CLL/hematology protocols.
MONITORING: CBC, renal dose, infection prophylaxis.
TR-HSCT-046MelphalanAlkylator · Tab/vial
Autologous HSCT conditioning for myeloma; oncology regimens.
MONITORING: CBC, mucositis, renal, cryotherapy.
TR-HSCT-047ThiotepaAlkylator · Vial
HSCT conditioning especially CNS disease protocols.
MONITORING: CBC, skin care, neuro.
TR-HSCT-048EtoposideTopoisomerase II inhibitor · Cap/vial
Conditioning and oncology regimens.
MONITORING: CBC, infusion, LFT.
TR-HSCT-049CytarabineAntimetabolite · Vial
Leukemia treatment; conditioning-related protocols.
MONITORING: CBC, neuro/cerebellar, renal/liver.
TR-HSCT-050Methotrexate low-doseAntimetabolite · Vial/tab
GVHD prophylaxis with calcineurin inhibitors in allogeneic HSCT.
MONITORING: CBC, LFT, renal, mucositis; leucovorin.
TR-HSCT-051AbataceptCTLA-4 modulator · IV/SC
FDA-approved prophylaxis of acute GVHD with CNI + methotrexate.
MONITORING: Infection screening; infusion.
TR-HSCT-052RuxolitinibJAK inhibitor · Tablet
Steroid-refractory acute GVHD; chronic GVHD per approvals.
MONITORING: CBC, infection, lipids, liver.
TR-HSCT-053BelumosudilROCK2 inhibitor · Tablet
Chronic GVHD after ≥2 prior systemic therapies.
MONITORING: LFT, drug interactions, infection.
TR-HSCT-054IbrutinibBTK inhibitor · Cap/tab
cGVHD after failure of prior therapy; hematology overlap.
MONITORING: Bleeding, AFib, infection.
TR-HSCT-055Axatilimab-csfrCSF-1R mAb · IV
cGVHD after ≥2 prior systemic therapies in eligible patients.
MONITORING: Infusion, LFT/enzymes, infection.
TR-HSCT-056Defibrotide sodiumEndothelial protective · IV
Hepatic VOD/SOS with renal/pulmonary dysfunction after HSCT.
MONITORING: Bleeding risk, organ function, ICU.
TR-HSCT-057Narsoplimab-wuugMASP-2 inhibitor · IV
HSCT-associated thrombotic microangiopathy in adults/children ≥2 years.
MONITORING: TMA labs, organ function, infection.
TR-HSCT-058Remestemcel-LMSC therapy · Cell infusion
Pediatric steroid-refractory acute GVHD.
MONITORING: Infusion, infection, certification.
TR-HSCT-059MesnaUroprotectant · IV/tab
Prevention of cyclophosphamide/ifosfamide hemorrhagic cystitis.
MONITORING: Urine output, hematuria, schedule.
TR-HSCT-060LeucovorinRescue agent · Tab/IV
Rescue after methotrexate, mucositis mitigation.
MONITORING: MTX timing, renal function.
TR-HSCT-061UrsodiolBile acid · Cap/tab
VOD/SOS risk reduction; cholestasis support.
MONITORING: LFTs, adherence.
Pillar · CMV · PJP · Fungal · HBV · HSV/VZV
Infection Prevention & Treatment
TR-INF-020ValganciclovirAntiviral anti-CMV · Tab/oral sol
CMV prophylaxis/pre-emptive therapy/treatment in SOT/HSCT.
MONITORING: CBC, renal dose adjustment, CMV viral load.
TR-INF-021Ganciclovir IVAntiviral anti-CMV · Vial / IV
Severe CMV disease or oral intolerance.
MONITORING: CBC, renal dosing, CMV viral load.
TR-INF-022LetermovirCMV terminase inhibitor · Tab/IV
HSCT CMV prophylaxis; restricted SOT prophylaxis when valganciclovir intolerant/resistant.
MONITORING: CMV viral load; resistance; drug interactions.
TR-INF-023MaribavirAnti-CMV UL97 inhibitor · Tablet
Refractory/resistant post-transplant CMV infection/disease.
MONITORING: CMV viral load weekly; TDM of interacting immunosuppressants.
TR-INF-024FoscarnetAntiviral anti-CMV/HSV · IV
Ganciclovir-resistant CMV or HSV where indicated.
MONITORING: Renal function, electrolytes, hydration.
TR-INF-025Acyclovir IV / oralAntiviral anti-HSV/VZV · Tab/IV
HSV/VZV prophylaxis/treatment; CNS disease IV.
MONITORING: Renal dose adjustment; neurotoxicity.
TR-INF-026ValacyclovirAntiviral anti-HSV/VZV · Tablet
HSV prophylaxis, VZV treatment, CMV low-risk alternatives.
MONITORING: Renal dose adjustment.
TR-INF-027Trimethoprim-sulfamethoxazoleAntibacterial/anti-PJP · Tab/susp
Pneumocystis prophylaxis; broad antimicrobial prophylaxis.
MONITORING: CBC, renal, potassium, allergy.
TR-INF-028DapsoneSulfone anti-PJP · Tablet
PJP prophylaxis when cotrimoxazole intolerant.
MONITORING: G6PD, CBC, methemoglobin.
TR-INF-029AtovaquoneAnti-PJP/antiprotozoal · Suspension
PJP prophylaxis/treatment alternative.
MONITORING: GI tolerance; admin with fat meal.
TR-INF-030Pentamidine isethionateAnti-PJP · Nebulized/IV
Inhaled or IV PJP prophylaxis/treatment alternative.
MONITORING: Respiratory monitoring; glucose; renal.
TR-INF-031FluconazoleAzole antifungal · Tab/IV
Candida prophylaxis/treatment; selected transplant protocols.
MONITORING: LFTs, QT, CNI interaction.
TR-INF-032PosaconazoleMold-active azole · Tab/susp/IV
Mold prophylaxis in high-risk HSCT/GVHD; salvage invasive fungal disease.
MONITORING: TDM, LFT, CNI/mTOR interactions.
TR-INF-033VoriconazoleMold-active azole · Tab/IV
Invasive aspergillosis; prophylaxis where indicated.
MONITORING: TDM, LFT, vision/neuro, CNI/mTOR interactions.
TR-INF-034Micafungin / echinocandinEchinocandin antifungal · IV
Candida and empiric antifungal coverage in neutropenia/critical care.
MONITORING: LFT, infusion, cultures.
TR-INF-035Liposomal amphotericin BPolyene antifungal · Vial / IV
Invasive fungal infection, cryptococcosis, mucormycosis, leishmaniasis.
MONITORING: Renal function, K/Mg, infusion reactions.
TR-INF-036EntecavirHBV antiviral · Tab/oral sol
HBV treatment/prophylaxis after liver/non-liver transplant; reactivation prevention.
MONITORING: HBV DNA, renal dose, LFT.
TR-INF-037Tenofovir disoproxil fumarateHBV/HIV antiviral · Tablet
HBV antiviral especially lamivudine resistance; HIV/HBV overlap.
MONITORING: Renal function, phosphate, bone health.
TR-INF-038Tenofovir alafenamideHBV antiviral · Tablet
Renal/bone-sparing HBV therapy for selected patients.
MONITORING: HBV DNA, LFT, renal.
TR-INF-039LamivudineHBV/HIV antiviral · Tab/sol
Legacy HBV prophylaxis in exceptional cases; HIV overlap.
MONITORING: HBV DNA, resistance monitoring, renal dose.
Pillar · Corneal · Ocular Surface · Skin / Burns
Tissue, Ocular & Graft Support
TR-TIS-072Prednisolone acetate ophthalmicOphthalmic steroid · Drops
Post-corneal graft anti-inflammatory immunosuppression.
MONITORING: IOP, infection, graft rejection signs.
TR-TIS-073Dexamethasone ophthalmicOphthalmic steroid · Drops/oint
Post-operative corneal/ocular tissue inflammation control.
MONITORING: IOP, infection.
TR-TIS-074Cyclosporine ophthalmicTopical immunomodulator · Drops
Dry eye and ocular surface immunomodulation after ocular procedures.
MONITORING: Ocular surface response, irritation.
TR-TIS-075Moxifloxacin ophthalmicOphthalmic antibiotic · Drops
Post-corneal graft/ocular procedure prophylaxis and infection treatment.
MONITORING: Infection signs, stewardship.
TR-TIS-076Lubricating eye dropsOcular surface support · Drops/gel
Ocular surface protection after corneal graft and dry eye.
MONITORING: Adherence, preservative sensitivity.
TR-TIS-077Timolol / brimonidine / dorzolamideIOP-lowering medicines · Drops
Steroid-induced ocular hypertension/glaucoma after ocular transplant.
MONITORING: IOP, bronchospasm/cardiac in beta blockers.
TR-TIS-078Silver sulfadiazineTopical antimicrobial · Cream
Burn wound infection prevention before/after skin grafting.
MONITORING: Wound status, allergy.
TR-TIS-079Mupirocin / fusidic acid topicalTopical antibiotic · Oint/cream
Local skin infection and decolonization support.
MONITORING: Stewardship, wound culture.
TR-TIS-080Chlorhexidine / povidone iodineAntiseptic/disinfectant · Sol/scrub
Skin prep and post-op wound infection prevention.
MONITORING: Allergy, proper dilution/contact time.
Pillar · Anaemia & Bone · CV · GI & Antiemesis
Continuity & Supportive Care
TR-SUP-062Ondansetron / palonosetronAntiemetic 5-HT3 antagonist · Tab/IV
Conditioning chemotherapy antiemesis and post-op nausea.
MONITORING: QT, constipation.
TR-SUP-063Aprepitant / fosaprepitantNK1 antiemetic · Cap/IV
High emetogenic conditioning/chemotherapy antiemesis.
MONITORING: CYP interactions with chemo/steroids.
TR-SUP-064Darbepoetin alfaESA · PFS
Anemia in failing kidney transplant/CKD and oncology/HSCT contexts.
MONITORING: Hb, BP, iron status.
TR-SUP-065Epoetin alfaESA · PFS/vial
Anemia of CKD/failing kidney transplant, post-transplant anemia.
MONITORING: Hb, BP, iron studies.
TR-SUP-066Iron sucrose / ferric carboxymaltoseIV iron · IV infusion
Iron deficiency correction with ESA support.
MONITORING: Ferritin/TSAT, hypersensitivity.
TR-SUP-067Magnesium replacementElectrolyte support · Oral/IV
Tacrolimus/cyclosporine-related hypomagnesemia and amphotericin support.
MONITORING: Mg, renal function.
TR-SUP-068Calcium + vitamin D / alfacalcidolBone/mineral support · Tab/cap
Steroid/CNI bone protection, CKD-MBD support.
MONITORING: Calcium, phosphate, renal function.
TR-SUP-069Atorvastatin / rosuvastatinLipid-lowering statin · Tablet
Post-transplant dyslipidemia from CNIs/mTOR/steroids.
MONITORING: Lipids, LFT, CK if symptoms.
TR-SUP-070Amlodipine / nifedipineCalcium-channel blocker · Tablet
CNI/steroid hypertension and renal protection pathway.
MONITORING: BP, edema, interactions.
TR-SUP-071Pantoprazole / omeprazolePPI · Tablet/IV
Steroid/NSAID/GI ulcer prophylaxis and supportive care.
MONITORING: Mg, C. difficile risk, long-term review.
Pillar · TDM Logistics · Pre-Transplant Readiness
Access Services
TR-OPS-081Transplant TDM service bundleService / diagnostics
Tacrolimus, cyclosporine, sirolimus, busulfan TDM logistics and reporting.
MONITORING: Turnaround time, critical alerts.
TR-OPS-082Vaccine pre-transplant readiness basketVaccines/immunization
HBV, pneumococcal, influenza, COVID-19, varicella where indicated before transplant.
MONITORING: Eligibility/timing; avoid live vaccines after transplant unless expert approval.
The Value Lens
What reliable access is worth.
In transplant, the expensive event is rarely the medicine — it is the avoidable complication. Continuity of supply, safety governance and fast rescue access reduce the total cost of care while protecting graft and life-years.
01
Continuity of supply
Uninterrupted CNI and prophylaxis supply protects against rejection episodes and infection-driven readmissions.
02
Healthy time protected
Adherence-friendly maintenance and predictable aftercare kits preserve graft function and productive time.
03
Affordability & financial toxicity
Planned sourcing reduces the financial shock of orphan rescue therapy for programmes and families.
04
Rescue access, on time
Pre-authorised pathways for VOD/SOS, TA-TMA and resistant CMV convert emergencies into governed access.
Consultant Note · Health Economics
“The honest economic case for a transplant formulary is avoided harm. Every prevented rejection, every uninterrupted prophylaxis course, every rescue therapy that arrives inside the clinical window is a cost the system never has to pay — and a patient outcome that holds.”
The Kenya & Region Lens
Kidney-first today. Multi-pathway ready.
Kidney transplantation is the practical anchor in Kenya, with national programmes expanding. Liver, heart/lung, HSCT, ocular and burn-graft access form the high-value pools that this formulary is already built to serve.
Verified, audit-ready device provenance for every line
Local stockholding for rapid, emergency dispatch
End-to-end visibility from manufacturer to patient
Current Anchor
Kidney Transplant
Living-donor programmes established; national kidney transplant services expanding. Induction and first-year maintenance baskets ready now.
Emerging Access
HSCT
Private and referral-driven; conditioning, GVHD and rescue depth positions the programme for growth.
Service-Aligned
Tissue & Ocular
Corneal and burn-graft support baskets align to eye-care and reconstructive surgery demand.
Built for What Comes Next
Liver, Heart, Lung
Access runs through planned cross-border sourcing and named-patient import pathways — visible and serviceable as local programmes mature.
Safety & Access Governance
Reliability you can document.
Every line passes a documented verification standard — critical for cytotoxics, biologics and controlled specialty products.
Registration-Checked
PPB-registered & quality-assured sourcing verified before listing. Every product confirmed before it enters your formulary.
End-to-End Cold Chain
Validated handling for cold-chain biologics. Controlled handling protects integrity from warehouse to pharmacy.
Batch Traceability
Batch traceability & audit-ready documentation on every order. The standard behind every line we supply.
Interaction & Safety
Narrow-therapeutic-index brand discipline, interaction flags and renal-dose guidance attached to relevant lines.
Stewardship Alignment
Antimicrobial cover aligned to WHO AWaRe and the Kenya Essential Medicines List.
Named-Patient Governance
Pre-prepared access dossiers and payer-aligned authorisation for orphan complications.
All supply, registration and clinical-use decisions remain subject to PPB registration verification, institutional formulary approval and transplant-team clinical judgement. Availability postures describe planning intent and supply governance, not guaranteed stock.
Start a Transplant Access Conversation
One route from protocol to patient.
Open a programme account early. Build the continuity baskets your protocols depend on, set the rescue pathways before they are needed.